TECX vs TNYA
TECX: A biotechnology company using its proprietary GEODe™ platform to unlock therapeutic protein and antibody treatments for difficult-to-target GPCR-related diseases. TNYA: Tenaya Therapeutics is a clinical-stage biopharmaceutical company leveraging gene therapy and small molecule platforms to develop curative, precision-medicine treatments for genetically defined heart diseases.
Side-by-side fundamentals
| Metric | TECX | TNYA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $30.61 | $0.7403 | |
| Market cap as of 2026-08-03 | $578M | $161M | |
| ROE as of 2026-08-03 | -32.3% | -80.6% | TECX higher |
| ROA as of 2026-08-03 | -30.9% | -65.2% | TECX higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.00 | TNYA lower |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-08-03 | 1.31 | 1.81 | |
| 1-year return as of 2026-07-27 close | +37.1% | +9.5% | TECX higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.